Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332072 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 541
- Enrollment target
- 1
- Study location
NCT00332072: Completed Phase 3 study of Ocular Hypertension, sponsored by Allergan.
NCT00332072 is a Phase 3 study of Ocular Hypertension that has completed, run by Allergan. The registered enrollment target is 541 participants, above the 268-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00332072, a Phase 3 study of Ocular Hypertension, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 541 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in the treatment of glaucoma or ocular hypertension
Conditions Studied
Interventions
- DRUG bimatoprost/timolol fixed combination
Study Locations (1)
Utah
- - Ogden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 541 participants |
| Start Date | 2001-08 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
What the finished NCT00332072 record still lists
NCT00332072 is an interventional study that assigns participants to a tested intervention. The registered 541 participants enrollment target is mid-sized for trials with a published cap, above the 268-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (102% higher).
The record links to 1 condition, with Ocular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which bimatoprost/timolol fixed combination is the first listed.
NCT00332072 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT00332072 about?
NCT00332072 is a clinical study titled "Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension". The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in the treatment of glaucoma or ocular hypertension
What is the current status of trial NCT00332072?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 541 participants. The study started on 2001-08. Estimated completion is 2003-08.
What conditions does trial NCT00332072 study?
This clinical trial studies the following conditions: Ocular Hypertension.
What interventions are being tested in trial NCT00332072?
The interventions under investigation include: bimatoprost/timolol fixed combination (DRUG).
Who is sponsoring clinical trial NCT00332072?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00332072 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00332072's enrollment target sits among peer trials
541 10th of 54 higher than 45 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04929223 · 542 participants · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia